Coherus Oncology
CHRS
188 hedge funds and large institutions have $1.54B invested in Coherus Oncology in 2020 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 65 increasing their positions, 55 reducing their positions, and 45 closing their positions.
27% more capital invested
Capital invested by funds: $1.21B → $1.54B (+$333M)
18% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 55
16.62% more ownership
Funds ownership: 105.75% → 122.37% (+17%)
1% more funds holding
Funds holding: 186 → 188 (+2)
9% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 45
32% less call options, than puts
Call options by funds: $1.73M | Put options by funds: $2.53M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$80.7M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$37.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.3M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$18.8M |
| 5 |
RI
Redwood Investments
Boston,
Massachusetts
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$32.8M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$25.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.1M |
| 4 |
HP
Hound Partners
New York
|
-$10.8M |
| 5 |
D.E. Shaw & Co
New York
|
-$10.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AL
226
AJO LP
Philadelphia,
Pennsylvania
| – | -$92K | -5,677 | Closed |
|
227
Ensign Peak Advisors
Salt Lake City,
Utah
| – | -$56K | -3,457 | Closed |
|
|
PCG
228
Private Capital Group
West Hartford,
Connecticut
| – | -$39K | -2,382 | Closed |
|
|
WAP
229
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$8K | -500 | Closed |
|
|
FMII
230
Farmers & Merchants Investments Inc
Lincoln,
Nebraska
| – | -$7K | -414 | Closed |
|
|
HNB
231
Huntington National Bank
Columbus,
Ohio
| – | -$4K | -274 | Closed |
|
|
IA
232
IFP Advisors
Tampa,
Florida
| – | -$2.73K | -161 | Closed |
|
|
CFGS
233
Concourse Financial Group Securities
Birmingham,
Alabama
| – | -$2.29K | -135 | Closed |
|
CHRS Hedge Fund Activity: Q2 2020 in Review
188 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2020, worth a combined $1.54B — up 27% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CHRS positions and 45 closed out — a net gain of 4 holders — while 65 added to existing stakes and 55 trimmed.
The largest buyer was BlackRock, adding an estimated $80.7M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $32.8M sold.
- 188 institutional investors held Coherus Oncology (CHRS) as of Q2 2020, up from 186 in Q1 2020.
- Funds reported $1.54B of Coherus Oncology stock for Q2 2020, up 27% quarter-over-quarter.
- 49 funds opened new Coherus Oncology positions in Q2 2020 and 45 closed out, a net change of +4 holders.
- The largest Coherus Oncology buyer in Q2 2020 was BlackRock, an estimated $80.7M added.
- The largest Coherus Oncology seller in Q2 2020 was Consonance Capital Management, an estimated $32.8M sold.
Based on aggregated 13F filings for Q2 2020.